Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ION224

Oligonucleotide (Antisense oligonucleotide) · developed by IONIS PHARMACEUTICALS

Phase 2 Most advanced trial (none active)

IONS Developer

1 Registered trials

What is ION224?

ION224 is an investigational oligonucleotide studied in Steatohepatitis, Nonalcoholic.

At a glance

Drug type: Oligonucleotide (Antisense oligonucleotide)
Therapy area: Gastroenterology
Developer: IONIS PHARMACEUTICALS (IONS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04932512	Phase 2	Steatohepatitis, Nonalcoholic	Completed	IONS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Steatohepatitis, Nonalcoholic

More from IONIS PHARMACEUTICALS

Donidalorsen FDA approved Olezarsen FDA approved Zilganersen FDA approved BIIB094 Phase 1 ION269 Phase 1 ION337 Phase 1/2 ION356 Phase 1 ION363 Phase 3 ION440 Phase 1/2 ION464 Phase 1 ION717 Phase 1/2 ION775 Phase 2

Sources

ClinicalTrials.gov NCT04932512

Updated Oct 3, 2026. Something wrong or missing? Report it on the IONS page.

Follow IONS, the company behind ION224

See IONS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IONS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z